Free Trial
NASDAQ:RLMD

Relmada Therapeutics Q3 2025 Earnings Report

Relmada Therapeutics logo
$2.20 +0.07 (+3.29%)
Closing price 10/9/2025 04:00 PM Eastern
Extended Trading
$2.17 -0.03 (-1.55%)
As of 05:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relmada Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.04
Beat/Miss
N/A
One Year Ago EPS
N/A

Relmada Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Relmada Therapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Relmada Therapeutics Earnings Headlines

Buy UBER immediately
BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on some of the biggest winners of 2025.tc pixel
See More Relmada Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Relmada Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relmada Therapeutics and other key companies, straight to your email.

About Relmada Therapeutics

Relmada Therapeutics (NASDAQ:RLMD) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings. In parallel, the company is advancing additional pipeline programs targeting neuropathic pain, including diabetic neuropathy and chemotherapy-induced peripheral neuropathy. Relmada collaborates with academic centers and contract research organizations to conduct multi-center trials across North America and Europe.

Headquartered in New York, Relmada Therapeutics was incorporated in Delaware and maintains its research operations in the United States. The company is led by a management team with extensive experience in biopharmaceutical development, regulatory strategy and commercial planning. Relmada’s common stock is listed on the NASDAQ under the symbol RLMD.

View Relmada Therapeutics Profile

More Earnings Resources from MarketBeat